Sixty percent of the participants in the intervention group were “no longer classified as clinical insomniacs” at the conclusion of the trial.
Region: Australia
Researchers said that their study was among the “largest and longest real-world analysis of the efficacy and safety” of medical cannabis products.
“Overall, it appears that there is limited scientific evidence to support the assertion that cannabis use impairs ‘next day’ performance,” researchers concluded.
Autistic patients exhibited significant improvements in communication and socialization skills, among other improvements.
Cannabis dosing was associated with reduced pain among all patients, with those suffering from bone metastasis experiencing the greatest levels of relief.
Survey data estimate that nearly one-third of patients suffering from chronic pain conditions acknowledge using cannabis products.
“By the end of treatment, the number of participants rated as markedly or severely ill had decreased from 17 to 5,” investigators reported.
Authors concluded: “[A]cute, oral CBD treatment at doses up to 1500 mg does not induce feelings of intoxication and is unlikely to impair cognitive function or driving performance.”